Paper20430010
3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines.
Qin JZ and 2 others. Biochem Biophys Res Commun, 2010. Cited by 45 papers, by iCite.
Cite this record
ConductScience Library. 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. Papers, record 20430010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20430010
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Apoptosis | Major topic |
| Melanoma | Major topic |
| Pyruvates | Major topic |
| Skin Neoplasms | Major topic |
| Acetylcysteine | |
| Adenosine Triphosphate | |
| Cell Line, Tumor | |
| Glutathione | |
| Humans | |
| Membrane Potential, Mitochondrial | |
| Necrosis | |
| Superoxides |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 45 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40563683 | KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40563683 | PubMed |
| 36555289 | 3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36555289 | PubMed |
| 35406733 | Mitochondrial Respiratory Complexes as Targets of Drugs: The PPAR Agonist Example. | Cells | 2022 | https://conductscience.org/library/papers/35406733 | PubMed |
| 33445795 | Delphinidin Increases the Sensitivity of Ovarian Cancer Cell Lines to 3-Bromopyruvate. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33445795 | PubMed |
| 30845728 | Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/30845728 | PubMed |
| 30154655 | Enhancing anticancer effects, decreasing risks and solving practical problems facing 3-bromopyruvate in clinical oncology: 10 years of research experience. | Int J Nanomedicine | 2018 | https://conductscience.org/library/papers/30154655 | PubMed |
| 27457582 | The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside. | J Bioenerg Biomembr | 2016 | https://conductscience.org/library/papers/27457582 | PubMed |
| 26986252 | Hexokinase 2 is a determinant of neuroblastoma metastasis. | Br J Cancer | 2016 | https://conductscience.org/library/papers/26986252 | PubMed |
| 26530987 | 3-Bromopyruvate induces rapid human prostate cancer cell death by affecting cell energy metabolism, GSH pool and the glyoxalase system. | J Bioenerg Biomembr | 2015 | https://conductscience.org/library/papers/26530987 | PubMed |
| 26387611 | The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes. | Sci Rep | 2015 | https://conductscience.org/library/papers/26387611 | PubMed |
| 26266544 | Differentiate or Die: 3-Bromopyruvate and Pluripotency in Mouse Embryonic Stem Cells. | PLoS One | 2015 | https://conductscience.org/library/papers/26266544 | PubMed |
| 24636230 | Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study. | Chin J Cancer | 2014 | https://conductscience.org/library/papers/24636230 | PubMed |
| 22802136 | D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects. | J Bioenerg Biomembr | 2012 | https://conductscience.org/library/papers/22802136 | PubMed |
| 22359102 | Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae. | J Bioenerg Biomembr | 2012 | https://conductscience.org/library/papers/22359102 | PubMed |
| 22350013 | Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. | J Bioenerg Biomembr | 2012 | https://conductscience.org/library/papers/22350013 | PubMed |
| 22328057 | Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. | J Bioenerg Biomembr | 2012 | https://conductscience.org/library/papers/22328057 | PubMed |
| 22318358 | Flow cytometric evaluation of the effects of 3-bromopyruvate (3BP) and dichloracetate (DCA) on THP-1 cells: a multiparameter analysis. | J Bioenerg Biomembr | 2012 | https://conductscience.org/library/papers/22318358 | PubMed |
| 22318357 | Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma cells. | J Bioenerg Biomembr | 2012 | https://conductscience.org/library/papers/22318357 | PubMed |
| 22298255 | 3-Bromopyruvate: targets and outcomes. | J Bioenerg Biomembr | 2012 | https://conductscience.org/library/papers/22298255 | PubMed |
| 21921941 | D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate. | Cancer Gene Ther | 2012 | https://conductscience.org/library/papers/21921941 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20430010
GET https://conductscience.org/api/papers/v1/20430010/cited_by?page=2